公开(公告)号：US10519234B2

公开(公告)日：2019-12-31

申请号：US15321650

申请日：2015-06-23

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US09427478B2

公开(公告)日：2016-08-30

申请号：US14582040

申请日：2014-12-23

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Laurent Gauthier ,  François Romagne ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/48 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  A61K31/5517

CPC classification number: A61K47/48569 ,  A61K31/5517 ,  A61K47/48384 ,  A61K47/48715 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/40

Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Abstract translation: 本申请涉及免疫球蛋白的酶官能化方法，特别是与药物的方法。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。

公开(公告)号：US20150344576A1

公开(公告)日：2015-12-03

申请号：US14829170

申请日：2015-08-18

Applicant: Novo Nordisk A/S - Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许哺乳动物受试者中NK细胞细胞毒性增强的抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US20150191547A1

公开(公告)日：2015-07-09

申请号：US14659045

申请日：2015-03-16

Applicant: Novo Nordisk A/S - Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C07K16/42

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

公开(公告)号：US20150165064A1

公开(公告)日：2015-06-18

申请号：US14582040

申请日：2014-12-23

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Laurent Gauthier ,  François Romagne ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/48 ,  A61K31/5517

CPC classification number: A61K47/48569 ,  A61K31/5517 ,  A61K47/48384 ,  A61K47/48715 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/40

Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Abstract translation: 本申请涉及免疫球蛋白的酶官能化方法，特别是与药物的方法。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。

公开(公告)号：US20130287770A1

公开(公告)日：2013-10-31

申请号：US13936486

申请日：2013-07-08

Applicant: INNATE PHARMA S.A.S. ,  NOVO-NORDISK A/S - NOVO ALLE

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Loius Spee ,  Milchael Wilken

IPC: C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US11891444B2

公开(公告)日：2024-02-06

申请号：US17315547

申请日：2021-05-10

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28 ,  C07K16/46 ,  C12N15/66 ,  C12N15/64 ,  C12N5/10 ,  C12N15/00

CPC classification number: C07K16/2803 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/468 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/526 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/92 ,  C12N2511/00 ,  C12N2523/00

Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20230416383A1

公开(公告)日：2023-12-28

申请号：US18308778

申请日：2023-04-28

Applicant: INNATE PHARMA ,  SANOFI

Inventor： Marielle CHIRON ,  Angela Virone-Oddos ,  Laurent Gauthier

IPC: C07K16/28 ,  A61P35/02 ,  A61K39/395

CPC classification number: C07K16/2866 ,  A61P35/02 ,  A61K39/395 ,  A61K39/3955 ,  C07K16/2896 ,  A61K2039/505

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).

公开(公告)号：US11377503B2

公开(公告)日：2022-07-05

申请号：US16443744

申请日：2019-06-17

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US11208480B2

公开(公告)日：2021-12-28

申请号：US15321674

申请日：2015-06-23

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Benjamin Rossi

IPC: C07K16/28 ,  C07K16/00 ,  C07K16/30

Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.